{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:07:24Z","timestamp":1778900844740,"version":"3.51.4"},"reference-count":184,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Rep"],"DOI":"10.3892\/or.2024.8733","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T07:36:02Z","timestamp":1712907362000},"source":"Crossref","is-referenced-by-count":15,"title":["Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)"],"prefix":"10.3892","volume":"51","author":[{"given":"Voraporn","family":"Yongprayoon","sequence":"first","affiliation":[{"name":"Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Napasporn","family":"Wattanakul","sequence":"additional","affiliation":[{"name":"Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnada","family":"Khomate","sequence":"additional","affiliation":[{"name":"Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathakrit","family":"Apithanangsiri","sequence":"additional","affiliation":[{"name":"Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarathip","family":"Kasitipradit","sequence":"additional","affiliation":[{"name":"Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danupon","family":"Nantajit","sequence":"additional","affiliation":[{"name":"Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahvash","family":"Tavassoli","sequence":"additional","affiliation":[{"name":"Centre for Host Microbiome Interactions, King's College London, London SE1 1UL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"key20240523092012_b1-or-51-6-08733","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"key20240523092012_b2-or-51-6-08733","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(10)70017-6","article-title":"HPV-associated head and neck cancer: A virus-related cancer epidemic","volume":"11","author":"Marur","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20240523092012_b3-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e202200343","DOI":"10.1002\/cmdc.202200343","article-title":"Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain","volume":"17","author":"Cipriano","year":"2022","journal-title":"ChemMedChem"},{"key":"key20240523092012_b4-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e2100180","DOI":"10.1002\/bies.202100180","article-title":"BRD4 in physiology and pathology: \u2018BET\u2019 on its partners","volume":"43","author":"Liang","year":"2021","journal-title":"Bioessays"},{"key":"key20240523092012_b5-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e2109133119","DOI":"10.1073\/pnas.2109133119","article-title":"BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240523092012_b6-or-51-6-08733","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.molcel.2017.04.027","article-title":"Bromodomain protein BRD4 is a transcriptional repressor of autophagy and lysosomal function","volume":"66","author":"Sakamaki","year":"2017","journal-title":"Mol Cell"},{"key":"key20240523092012_b7-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41419-022-05505-1","article-title":"Regulation of programmed cell death by Brd4","volume":"13","author":"Hu","year":"2022","journal-title":"Cell Death Dis"},{"key":"key20240523092012_b8-or-51-6-08733","doi-asserted-by":"publisher","first-page":"847701","DOI":"10.3389\/fonc.2022.847701","article-title":"Post-Translational modifications of BRD4: Therapeutic targets for tumor","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"key20240523092012_b9-or-51-6-08733","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET inhibitors in the treatment of hematologic malignancies: Current insights and future prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"Onco Targets Ther"},{"key":"key20240523092012_b10-or-51-6-08733","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/13543776.2020.1702645","article-title":"A patent review of BRD4 inhibitors (2013\u20132019)","volume":"30","author":"Lu","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"key20240523092012_b11-or-51-6-08733","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/pin.12727","article-title":"NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol Int"},{"key":"key20240523092012_b12-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e100293","DOI":"10.15252\/embj.2018100293","article-title":"BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses","volume":"38","author":"Dey","year":"2019","journal-title":"EMBO J"},{"key":"key20240523092012_b13-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1128\/MCB.22.11.3794-3802.2002","article-title":"Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4","volume":"22","author":"Houzelstein","year":"2002","journal-title":"Mol Cell Biol"},{"key":"key20240523092012_b14-or-51-6-08733","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12864-016-2414-y","article-title":"Histone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells","volume":"17","author":"Gonzales-Cope","year":"2016","journal-title":"BMC Genomics"},{"key":"key20240523092012_b15-or-51-6-08733","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"key20240523092012_b16-or-51-6-08733","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1189\/jlb.2RI0616-250R","article-title":"Bromodomain 4: A cellular swiss army knife","volume":"100","author":"Devaiah","year":"2016","journal-title":"J Leukoc Biol"},{"key":"key20240523092012_b17-or-51-6-08733","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1073\/pnas.1120422109","article-title":"BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain","volume":"109","author":"Devaiah","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240523092012_b18-or-51-6-08733","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/19491034.2022.2038868","article-title":"Mechanical determinants of chromatin topology and gene expression","volume":"13","author":"Jha","year":"2022","journal-title":"Nucleus"},{"key":"key20240523092012_b19-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nsmb.2912","article-title":"BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones","volume":"21","author":"Kanno","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"key20240523092012_b20-or-51-6-08733","doi-asserted-by":"publisher","first-page":"9059","DOI":"10.1128\/MCB.24.20.9059-9069.2004","article-title":"Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization","volume":"24","author":"Farina","year":"2004","journal-title":"Mol Cell Biol"},{"key":"key20240523092012_b21-or-51-6-08733","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1128\/MCB.00299-09","article-title":"Regulation of aurora B expression by the bromodomain protein Brd4","volume":"29","author":"You","year":"2009","journal-title":"Mol Cell Biol"},{"key":"key20240523092012_b22-or-51-6-08733","first-page":"E5352","article-title":"Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma","volume":"114","author":"Wang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240523092012_b23-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.7150\/thno.31581","article-title":"Therapeutic targeting of BRD4 in head neck squamous cell carcinoma","volume":"9","author":"Wu","year":"2019","journal-title":"Theranostics"},{"key":"key20240523092012_b24-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","article-title":"Opposing functions of BRD4 isoforms in breast cancer","volume":"78","author":"Wu","year":"2020","journal-title":"Mol Cell"},{"key":"key20240523092012_b25-or-51-6-08733","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-021-01424-5","article-title":"The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis","volume":"20","author":"Drumond-Bock","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240523092012_b26-or-51-6-08733","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cellimm.2019.02.001","article-title":"Emerging roles of and therapeutic strategies targeting BRD4 in cancer","volume":"337","author":"White","year":"2019","journal-title":"Cell Immunol"},{"key":"key20240523092012_b27-or-51-6-08733","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: Going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"key":"key20240523092012_b28-or-51-6-08733","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"key20240523092012_b29-or-51-6-08733","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/sci-2022-033","article-title":"BRD4 regulates the induction and maintenance of cancer stem cells in squamous cell carcinoma","volume":"9","author":"Hamad","year":"2022","journal-title":"Stem Cell Investig"},{"key":"key20240523092012_b30-or-51-6-08733","doi-asserted-by":"publisher","first-page":"280","DOI":"10.15252\/embr.201439949","article-title":"Oncogene addiction: Pathways of therapeutic response, resistance, and road maps toward a cure","volume":"16","author":"Pagliarini","year":"2015","journal-title":"EMBO Rep"},{"key":"key20240523092012_b31-or-51-6-08733","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccr.2014.01.028","article-title":"Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer","volume":"25","author":"Shi","year":"2014","journal-title":"Cancer Cell"},{"key":"key20240523092012_b32-or-51-6-08733","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1158\/0008-5472.CAN-16-0559","article-title":"BRD4 regulates breast cancer dissemination through Jagged1\/Notch1 signaling","volume":"76","author":"Andrieu","year":"2016","journal-title":"Cancer Res"},{"key":"key20240523092012_b33-or-51-6-08733","doi-asserted-by":"publisher","first-page":"128","DOI":"10.18231\/j.jdpo.2020.027","article-title":"Role of BRD4 in cancer-A review","volume":"5","author":"Samani","year":"2020","journal-title":"J Diagnostic Pathol Oncolo"},{"key":"key20240523092012_b34-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br J Cancer"},{"key":"key20240523092012_b35-or-51-6-08733","first-page":"2503","article-title":"Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression","volume":"53","author":"Tan","year":"2018","journal-title":"Int J Oncol"},{"key":"key20240523092012_b36-or-51-6-08733","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/tox.22873","article-title":"BRD4 promotes glioma cell stemness via enhancing miR-142-5p-mediated activation of Wnt\/\u03b2-catenin signaling","volume":"35","author":"Wang","year":"2020","journal-title":"Environ Toxicol"},{"key":"key20240523092012_b37-or-51-6-08733","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41419-022-05269-8","article-title":"EGFR-induced suppression of HPV E6\/E7 is mediated by microRNA-9-5p silencing of BRD4 protein in HPV-positive head and neck squamous cell carcinoma","volume":"13","author":"Nantajit","year":"2022","journal-title":"Cell Death Dis"},{"key":"key20240523092012_b38-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood.2022019274","article-title":"BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis","volume":"142","author":"Schmitt","year":"2023","journal-title":"Blood"},{"key":"key20240523092012_b39-or-51-6-08733","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","article-title":"Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628","volume":"6","author":"Stathis","year":"2016","journal-title":"Cancer Discov"},{"key":"key20240523092012_b40-or-51-6-08733","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbrc.2022.03.039","article-title":"BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma","volume":"604","author":"Zhang","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"key20240523092012_b41-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1158\/0008-5472.CAN-19-3674","article-title":"BRD4 levels determine the response of human lung cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1","volume":"80","author":"Zong","year":"2020","journal-title":"Cancer Res"},{"key":"key20240523092012_b42-or-51-6-08733","first-page":"530","article-title":"Degradation of BRD4-a promising treatment approach not only for hematologic but also for solid cancer","volume":"11","author":"Bauer","year":"2021","journal-title":"Am J Cancer Res"},{"key":"key20240523092012_b43-or-51-6-08733","doi-asserted-by":"publisher","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","article-title":"Safety and efficacy of bromodomain and Extra-Terminal inhibitors for the treatment of hematological malignancies and solid tumors: A systematic study of clinical trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front Pharmacol"},{"key":"key20240523092012_b44-or-51-6-08733","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature12147","article-title":"The bromodomain protein Brd4 insulates chromatin from DNA damage signalling","volume":"498","author":"Floyd","year":"2013","journal-title":"Nature"},{"key":"key20240523092012_b45-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/s41388-021-01735-3","article-title":"BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair","volume":"40","author":"Ni","year":"2021","journal-title":"Oncogene"},{"key":"key20240523092012_b46-or-51-6-08733","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1038\/s41467-020-17503-y","article-title":"BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"key20240523092012_b47-or-51-6-08733","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","article-title":"BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer","volume":"22","author":"Li","year":"2018","journal-title":"Cell Rep"},{"key":"key20240523092012_b48-or-51-6-08733","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","article-title":"BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"key20240523092012_b49-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1038\/s41467-022-30787-6","article-title":"BRD4 promotes resection and homology-directed repair of DNA double-strand breaks","volume":"13","author":"Barrows","year":"2022","journal-title":"Nat Commun"},{"key":"key20240523092012_b50-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/ijc.32515","article-title":"Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer","volume":"146","author":"Takashima","year":"2020","journal-title":"Int J Cancer"},{"key":"key20240523092012_b51-or-51-6-08733","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41419-020-2431-2","article-title":"Inhibition of BRD4 prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis","volume":"11","author":"Tan","year":"2020","journal-title":"Cell Death Dis"},{"key":"key20240523092012_b52-or-51-6-08733","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ebiom.2019.05.035","article-title":"The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors","volume":"44","author":"Miller","year":"2019","journal-title":"EBioMedicine"},{"key":"key20240523092012_b53-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s41388-022-02176-2","article-title":"BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage","volume":"41","author":"He","year":"2022","journal-title":"Oncogene"},{"key":"key20240523092012_b54-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s10620-023-07907-3","article-title":"High expression level of BRD4 is associated with a poor prognosis and immune infiltration in esophageal squamous cell carcinoma","volume":"68","author":"Li","year":"2023","journal-title":"Dig Dis Sci"},{"key":"key20240523092012_b55-or-51-6-08733","doi-asserted-by":"publisher","first-page":"9491","DOI":"10.18632\/oncotarget.7068","article-title":"High level of BRD4 promotes non-small cell lung cancer progression","volume":"7","author":"Liao","year":"2016","journal-title":"Oncotarget"},{"key":"key20240523092012_b56-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.3390\/cancers13133118","article-title":"Prevalence of DNA repair gene mutations in blood and tumor tissue and impact on prognosis and treatment in HNSCC","volume":"13","author":"Burcher","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20240523092012_b57-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-10-2641","article-title":"DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy","volume":"17","author":"Moeller","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20240523092012_b58-or-51-6-08733","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1007\/s13277-014-1792-5","article-title":"Deregulation of base excision repair gene expression and enhanced proliferation in head and neck squamous cell carcinoma","volume":"35","author":"Mahjabeen","year":"2014","journal-title":"Tumour Biol"},{"key":"key20240523092012_b59-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/cancers13061194","article-title":"DNA damage response during replication correlates with CIN70 score and determines survival in HNSCC patients","volume":"13","author":"Bold","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20240523092012_b60-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e2314132","DOI":"10.1002\/adma.202314132","article-title":"PROTAC Prodrug-Integrated nanosensitizer for potentiating radiation therapy of cancer","author":"Zhang","year":"2024","journal-title":"Adv Mater"},{"key":"key20240523092012_b61-or-51-6-08733","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2017.01.031","article-title":"The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21","volume":"391","author":"Wang","year":"2017","journal-title":"Cancer Lett"},{"key":"key20240523092012_b62-or-51-6-08733","doi-asserted-by":"publisher","first-page":"925718","DOI":"10.3389\/fonc.2022.925718","article-title":"The BET inhibitor JQ1 potentiates the anticlonogenic effect of radiation in pancreatic cancer Cells","volume":"12","author":"Garcia","year":"2022","journal-title":"Front Oncol"},{"key":"key20240523092012_b63-or-51-6-08733","doi-asserted-by":"publisher","first-page":"13062","DOI":"10.3390\/ijms241713062","article-title":"BRD4 inhibition enhances the antitumor effects of radiation therapy in a murine breast cancer model","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20240523092012_b64-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.3390\/jcm8122131","article-title":"Hippo pathway and YAP signaling alterations in squamous cancer of the head and neck","volume":"8","author":"Santos-de-Frutos","year":"2019","journal-title":"J Clin Med"},{"key":"key20240523092012_b65-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3892\/or.2015.4410","article-title":"JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms","volume":"35","author":"Choi","year":"2016","journal-title":"Oncol Rep"},{"key":"key20240523092012_b66-or-51-6-08733","doi-asserted-by":"publisher","first-page":"32628","DOI":"10.18632\/oncotarget.8701","article-title":"Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer","volume":"7","author":"Hong","year":"2016","journal-title":"Oncotarget"},{"key":"key20240523092012_b67-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1016\/j.molcel.2023.06.032","article-title":"Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation","volume":"83","author":"Zheng","year":"2023","journal-title":"Mol Cell"},{"key":"key20240523092012_b68-or-51-6-08733","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1093\/nar\/gku449","article-title":"Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation","volume":"42","author":"Itzen","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"key20240523092012_b69-or-51-6-08733","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jconrel.2022.12.035","article-title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy","volume":"354","author":"He","year":"2023","journal-title":"J Control Release"},{"key":"key20240523092012_b70-or-51-6-08733","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1139\/bcb-2021-0552","article-title":"BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance","volume":"100","author":"Liu","year":"2022","journal-title":"Biochem Cell Biol"},{"key":"key20240523092012_b71-or-51-6-08733","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41418-019-0353-2","article-title":"Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail","volume":"27","author":"Lu","year":"2020","journal-title":"Cell Death Differ"},{"key":"key20240523092012_b72-or-51-6-08733","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41391-020-0246-y","article-title":"BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer","volume":"24","author":"Shafran","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key20240523092012_b73-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.2174\/1381612821666141211153853","article-title":"Twist-BRD4 complex: Potential drug target for basal-like breast cancer","volume":"21","author":"Shi","year":"2015","journal-title":"Curr Pharm Des"},{"key":"key20240523092012_b74-or-51-6-08733","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0394632015572070","article-title":"BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"28","author":"Zhang","year":"2015","journal-title":"Int J Immunopathol Pharmacol"},{"key":"key20240523092012_b75-or-51-6-08733","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/1541-7786.MCR-17-0568","article-title":"BET proteins exhibit transcriptional and functional opposition in the Epithelial-to-Mesenchymal transition","volume":"16","author":"Andrieu","year":"2018","journal-title":"Mol Cancer Res"},{"key":"key20240523092012_b76-or-51-6-08733","doi-asserted-by":"publisher","first-page":"L1183","DOI":"10.1152\/ajplung.00224.2016","article-title":"BRD4 mediates NF-\u03baB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation","volume":"311","author":"Tian","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key20240523092012_b77-or-51-6-08733","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.3390\/ijms21186873","article-title":"Combination of ACY-241 and JQ1 synergistically suppresses metastasis of HNSCC via regulation of MMP-2 and MMP-9","volume":"21","author":"Cho","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20240523092012_b78-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3390\/ijms16011928","article-title":"BRD4 inhibitor inhibits colorectal cancer growth and metastasis","volume":"16","author":"Hu","year":"2015","journal-title":"Int J Mol Sci"},{"key":"key20240523092012_b79-or-51-6-08733","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40659-017-0124-9","article-title":"BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma","volume":"50","author":"Wang","year":"2017","journal-title":"Biol Res"},{"key":"key20240523092012_b80-or-51-6-08733","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41416-020-0907-6","article-title":"BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene","volume":"123","author":"Yamamoto","year":"2020","journal-title":"Br J Cancer"},{"key":"key20240523092012_b81-or-51-6-08733","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells11030561","article-title":"Mechanisms of cisplatin resistance in HPV negative head and neck squamous cell carcinomas","volume":"11","author":"Griso","year":"2022","journal-title":"Cells"},{"key":"key20240523092012_b82-or-51-6-08733","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-0348-0837-8_5","article-title":"The role of inflammation in head and neck cancer","volume":"816","author":"Bonomi","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"key20240523092012_b83-or-51-6-08733","doi-asserted-by":"publisher","first-page":"112620","DOI":"10.1016\/j.ecoenv.2021.112620","article-title":"The epigenetic regulator BRD4 is involved in cadmium-triggered inflammatory response in rat kidney","volume":"224","author":"Gong","year":"2021","journal-title":"Ecotoxicol Environ Saf"},{"key":"key20240523092012_b84-or-51-6-08733","doi-asserted-by":"publisher","first-page":"E3993","DOI":"10.1073\/pnas.1700109114","article-title":"Brd4 modulates the innate immune response through Mnk2-eIF4E pathway-dependent translational control of I\u03baB\u03b1","volume":"114","author":"Bao","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240523092012_b85-or-51-6-08733","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.tcb.2014.09.005","article-title":"Brd4 is on the move during inflammation","volume":"24","author":"Xu","year":"2014","journal-title":"Trends Cell Biol"},{"key":"key20240523092012_b86-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.3390\/cells11193086","article-title":"Influence of shear stress, inflammation and BRD4 inhibition on human endothelial cells: A holistic proteomic approach","volume":"11","author":"Jarausch","year":"2022","journal-title":"Cells"},{"key":"key20240523092012_b87-or-51-6-08733","doi-asserted-by":"publisher","first-page":"609319","DOI":"10.3389\/fimmu.2021.609319","article-title":"JQ1 as a BRD4 inhibitor blocks inflammatory pyroptosis-related acute colon injury induced by LPS","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"key20240523092012_b88-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"key20240523092012_b89-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e95051","DOI":"10.1371\/journal.pone.0095051","article-title":"Brd4 is essential for IL-1\u03b2-induced inflammation in human airway epithelial cells","volume":"9","author":"Khan","year":"2014","journal-title":"PLoS One"},{"key":"key20240523092012_b90-or-51-6-08733","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2023.06.003","article-title":"Inflammatory response-related genes predict prognosis in patients with HNSCC","volume":"259","author":"Jing","year":"2023","journal-title":"Immunol Lett"},{"key":"key20240523092012_b91-or-51-6-08733","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hed.23567","article-title":"Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma","volume":"37","author":"Rassouli","year":"2015","journal-title":"Head Neck"},{"key":"key20240523092012_b92-or-51-6-08733","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/fon-2020-0010","article-title":"Prognostic value of systemic inflammatory marker in patients with head and neck squamous cell carcinoma undergoing surgical resection","volume":"16","author":"Zhou","year":"2020","journal-title":"Future Oncol"},{"key":"key20240523092012_b93-or-51-6-08733","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12885-016-2089-4","article-title":"Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients","volume":"16","author":"Charles","year":"2016","journal-title":"BMC Cancer"},{"key":"key20240523092012_b94-or-51-6-08733","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/jso.26687","article-title":"Epidemiology and incidence of HPV-related cancers of the head and neck","volume":"124","author":"Roman","year":"2021","journal-title":"J Surg Oncol"},{"key":"key20240523092012_b95-or-51-6-08733","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"key20240523092012_b96-or-51-6-08733","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1590\/1414-431X20132703","article-title":"Impact of HPV infection on the development of head and neck cancer","volume":"46","author":"Betiol","year":"2013","journal-title":"Braz J Med Biol Res"},{"key":"key20240523092012_b97-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"key20240523092012_b98-or-51-6-08733","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fmicb.2012.00152","article-title":"Productive lifecycle of human papillomaviruses that depends upon squamous epithelial differentiation","volume":"3","author":"Kajitani","year":"2012","journal-title":"Front Microbiol"},{"key":"key20240523092012_b99-or-51-6-08733","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jviromet.2009.01.005","article-title":"Disruption of HPV 16 E1 and E2 genes in precancerous cervical lesions","volume":"158","author":"Cricca","year":"2009","journal-title":"J Virol Methods"},{"key":"key20240523092012_b100-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human Papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2019","journal-title":"Front Microbiol"},{"key":"key20240523092012_b101-or-51-6-08733","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.3390\/ijms23094943","article-title":"HPV16 and HPV18 genome structure, expression, and Post-Transcriptional regulation","volume":"23","author":"Yu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20240523092012_b102-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.3390\/v6083228","article-title":"The cellular bromodomain protein Brd4 has multiple functions in E2-mediated papillomavirus transcription activation","volume":"6","author":"Helfer","year":"2014","journal-title":"Viruses"},{"key":"key20240523092012_b103-or-51-6-08733","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.tim.2004.10.002","article-title":"Brd4: Tethering, segregation and beyond","volume":"12","author":"McBride","year":"2004","journal-title":"Trends Microbiol"},{"key":"key20240523092012_b104-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e1004117","DOI":"10.1371\/journal.ppat.1004117","article-title":"Papillomavirus genomes associate with BRD4 to replicate at fragile sites in the host genome","volume":"10","author":"Jang","year":"2014","journal-title":"PLoS Pathog"},{"key":"key20240523092012_b105-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3390\/v5061374","article-title":"Current understanding of the role of the Brd4 protein in the papillomavirus lifecycle","volume":"5","author":"McBride","year":"2013","journal-title":"Viruses"},{"key":"key20240523092012_b106-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e01644","DOI":"10.1128\/mBio.01644-16","article-title":"Brd4 activates early viral transcription upon human papillomavirus 18 infection of primary keratinocytes","volume":"7","author":"McKinney","year":"2016","journal-title":"mBio"},{"key":"key20240523092012_b107-or-51-6-08733","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.virusres.2016.12.006","article-title":"Involvement of Brd4 in different steps of the papillomavirus life cycle","volume":"231","author":"Iftner","year":"2017","journal-title":"Virus Res"},{"key":"key20240523092012_b108-or-51-6-08733","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.antiviral.2018.03.012","article-title":"BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo","volume":"154","author":"Morse","year":"2018","journal-title":"Antiviral Res"},{"key":"key20240523092012_b109-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e1008429","DOI":"10.1371\/journal.ppat.1008429","article-title":"BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses","volume":"16","author":"Wang","year":"2020","journal-title":"PLoS Pathog"},{"key":"key20240523092012_b110-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e1011089","DOI":"10.1371\/journal.ppat.1011089","article-title":"Oncolytic strategy using new bifunctional HDACs\/BRD4 inhibitors against virus-associated lymphomas","volume":"19","author":"Chen","year":"2023","journal-title":"PLoS Pathog"},{"key":"key20240523092012_b111-or-51-6-08733","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20240523092012_b112-or-51-6-08733","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3389\/fonc.2019.00815","article-title":"Best practice in systemic therapy for head and neck squamous cell carcinoma","volume":"9","author":"Oosting","year":"2019","journal-title":"Front Oncol"},{"key":"key20240523092012_b113-or-51-6-08733","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1634\/theoncologist.2020-0303","article-title":"Optimizing treatment De-Escalation in head and neck cancer: Current and future perspectives","volume":"26","author":"Rosenberg","year":"2021","journal-title":"Oncologist"},{"key":"key20240523092012_b114-or-51-6-08733","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.clon.2022.03.009","article-title":"Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis","volume":"34","author":"Swain","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"key20240523092012_b115-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/cam4.2772","article-title":"EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2","volume":"9","author":"Lv","year":"2020","journal-title":"Cancer Med"},{"key":"key20240523092012_b116-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-16-0243","article-title":"EGFR and RB1 as dual biomarkers in HPV-Negative head and neck cancer","volume":"15","author":"Beck","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"key20240523092012_b117-or-51-6-08733","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2020.10.035","article-title":"EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation","volume":"498","author":"Alsahafi","year":"2021","journal-title":"Cancer Lett"},{"key":"key20240523092012_b118-or-51-6-08733","first-page":"47","article-title":"The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective","volume":"17","author":"Rieckmann","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"key20240523092012_b119-or-51-6-08733","first-page":"75","article-title":"The dogma of Cetuximab and Radiotherapy in head and neck cancer-A dawn to dusk journey","volume":"34","author":"Krishnamurthy","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"key20240523092012_b120-or-51-6-08733","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.bbrc.2018.03.184","article-title":"AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo","volume":"499","author":"Xu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"key20240523092012_b121-or-51-6-08733","first-page":"75","article-title":"MYC as therapeutic target in leukemia and lymphoma","volume":"5","author":"Cortiguera","year":"2015","journal-title":"Blood and Lymphatic Cancer: Targets and Therapy"},{"key":"key20240523092012_b122-or-51-6-08733","first-page":"4179","article-title":"miR-204 enhances p27 mRNA stability by targeting Brd4 in head and neck squamous cell carcinoma","volume":"16","author":"Wang","year":"2018","journal-title":"Oncol Lett"},{"key":"key20240523092012_b123-or-51-6-08733","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.canlet.2019.11.027","article-title":"Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma","volume":"469","author":"Zhang","year":"2020","journal-title":"Cancer Lett"},{"key":"key20240523092012_b124-or-51-6-08733","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2019.06.019","article-title":"Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence","volume":"461","author":"Webber","year":"2019","journal-title":"Cancer Lett"},{"key":"key20240523092012_b125-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-021-24137-1","article-title":"Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma","volume":"12","author":"Dong","year":"2021","journal-title":"Nat Commun"},{"key":"key20240523092012_b126-or-51-6-08733","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12935-021-02060-1","article-title":"JOSD1 promotes proliferation and chemoresistance of head and neck squamous cell carcinoma under the epigenetic regulation of BRD4","volume":"21","author":"Jing","year":"2021","journal-title":"Cancer Cell Int"},{"key":"key20240523092012_b127-or-51-6-08733","doi-asserted-by":"publisher","first-page":"110970","DOI":"10.1016\/j.celrep.2022.110970","article-title":"YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4","volume":"39","author":"Chen","year":"2022","journal-title":"Cell Rep"},{"key":"key20240523092012_b128-or-51-6-08733","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-0459","article-title":"BET Inhibition overcomes receptor tyrosine Kinase-Mediated cetuximab resistance in HNSCC","volume":"78","author":"Leonard","year":"2018","journal-title":"Cancer Res"},{"key":"key20240523092012_b129-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/cells10092245","article-title":"Annexin A1 as a regulator of immune response in cancer","volume":"10","author":"Araujo","year":"2021","journal-title":"Cells"},{"key":"key20240523092012_b130-or-51-6-08733","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/bcpt.13481","article-title":"Bromodomain 4 is a potent prognostic marker associated with immune cell infiltration in breast cancer","volume":"128","author":"Zhong","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20240523092012_b131-or-51-6-08733","doi-asserted-by":"publisher","first-page":"17541","DOI":"10.18632\/aging.103768","article-title":"BRD4\/8\/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma","volume":"12","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"key20240523092012_b132-or-51-6-08733","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1186\/s12885-018-4653-6","article-title":"Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"key20240523092012_b133-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/jcb.29420","article-title":"Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma","volume":"121","author":"Zhao","year":"2020","journal-title":"J Cell Biochem"},{"key":"key20240523092012_b134-or-51-6-08733","doi-asserted-by":"publisher","first-page":"112034","DOI":"10.1016\/j.yexcr.2020.112034","article-title":"BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer","volume":"392","author":"Jing","year":"2020","journal-title":"Exp Cell Res"},{"key":"key20240523092012_b135-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1042490","DOI":"10.3389\/fcell.2023.1042490","article-title":"Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme","volume":"11","author":"Ye","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"key20240523092012_b136-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1002\/hed.26827","article-title":"PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance","volume":"43","author":"Bhola","year":"2021","journal-title":"Head Neck"},{"key":"key20240523092012_b137-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1016\/j.ymthe.2022.07.022","article-title":"BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol Ther"},{"key":"key20240523092012_b138-or-51-6-08733","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1681\/ASN.2015080910","article-title":"Inhibition of bromodomain and extraterminal domain family proteins ameliorates experimental renal damage","volume":"28","author":"Suarez-Alvarez","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key20240523092012_b139-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1016\/j.ymthe.2021.05.019","article-title":"BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma","volume":"29","author":"Xia","year":"2021","journal-title":"Mol Ther"},{"key":"key20240523092012_b140-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/1535-7163.MCT-18-1206","article-title":"SF2523: Dual PI3K\/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer","volume":"18","author":"Joshi","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"key20240523092012_b141-or-51-6-08733","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fimmu.2020.00089","article-title":"BRD4 Inhibition by AZD5153 promotes antitumor immunity via depolarizing M2 macrophages","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"key20240523092012_b142-or-51-6-08733","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"key20240523092012_b143-or-51-6-08733","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"key":"key20240523092012_b144-or-51-6-08733","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41389-021-00316-z","article-title":"Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4","volume":"10","author":"Calder","year":"2021","journal-title":"Oncogenesis"},{"key":"key20240523092012_b145-or-51-6-08733","doi-asserted-by":"publisher","first-page":"592e594","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4","volume":"71","author":"Jin","year":"2018","journal-title":"Mol Cell"},{"key":"key20240523092012_b146-or-51-6-08733","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41467-019-14083-4","article-title":"Enhanced JunD\/RSK3 signalling due to loss of BRD4\/FOXD3\/miR-548d-3p axis determines BET inhibition resistance","volume":"11","author":"Tai","year":"2020","journal-title":"Nat Commun"},{"key":"key20240523092012_b147-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.ajpath.2022.06.010","article-title":"ZNF33A promotes tumor progression and BET inhibitor resistance in Triple-Negative breast cancer","volume":"192","author":"Wang","year":"2022","journal-title":"Am J Pathol"},{"key":"key20240523092012_b148-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","article-title":"Synthetic lethal and resistance interactions with BET bromodomain inhibitors in Triple-Negative breast cancer","volume":"78","author":"Shu","year":"2020","journal-title":"Mol Cell"},{"key":"key20240523092012_b149-or-51-6-08733","doi-asserted-by":"publisher","first-page":"8063","DOI":"10.2147\/OTT.S236659","article-title":"Akt\/mTOR-Mediated autophagy confers resistance to BET inhibitor JQ1 in ovarian cancer","volume":"12","author":"Luan","year":"2019","journal-title":"Onco Targets Ther"},{"key":"key20240523092012_b150-or-51-6-08733","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13402-020-00578-6","article-title":"Clinical perspectives of BET inhibition in ovarian cancer","volume":"44","author":"Andrikopoulou","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"key20240523092012_b151-or-51-6-08733","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13046-018-0888-y","article-title":"FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma","volume":"37","author":"Wang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"key20240523092012_b152-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat Med"},{"key":"key20240523092012_b153-or-51-6-08733","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-Human study of mivebresib (ABBV-075), an Oral Pan-Inhibitor of bromodomain and extra terminal proteins, in patients with Relapsed\/Refractory solid tumors","volume":"25","author":"Piha-Paul","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20240523092012_b154-or-51-6-08733","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A Phase Ib\/IIa Study of the Pan-BET Inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic Castration-Resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20240523092012_b155-or-51-6-08733","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"key20240523092012_b156-or-51-6-08733","doi-asserted-by":"publisher","first-page":"103628","DOI":"10.1016\/j.critrevonc.2022.103628","article-title":"New advances in exosome-based targeted drug delivery systems","volume":"172","author":"Ferreira","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20240523092012_b157-or-51-6-08733","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.canlet.2018.02.002","article-title":"Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer","volume":"420","author":"Bhome","year":"2018","journal-title":"Cancer Lett"},{"key":"key20240523092012_b158-or-51-6-08733","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12032-022-01858-x","article-title":"HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model","volume":"39","author":"Alcitepe","year":"2022","journal-title":"Med Oncol"},{"key":"key20240523092012_b159-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/cas.14102","article-title":"BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo","volume":"110","author":"Liu","year":"2019","journal-title":"Cancer Sci"},{"key":"key20240523092012_b160-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood-2019-124741","article-title":"Phase 1 Dose escalation and expansion study to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of the BET inhibitor FT-1101 as a single agent in patients with relapsed or refractory hematologic malignancies","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"key20240523092012_b161-or-51-6-08733","doi-asserted-by":"publisher","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and Extra-Terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"key20240523092012_b162-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"A Phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) Inhibitor: Results from Part 1 of Phase I\/II open label single agent study in patients with acute myeloid leukemia (AML)","volume":"130","author":"Dawson","year":"2017","journal-title":"Blood"},{"key":"key20240523092012_b163-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","article-title":"Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20240523092012_b164-or-51-6-08733","doi-asserted-by":"publisher","first-page":"e1792906","DOI":"10.1097\/01.HS9.0000971116.17929.06","article-title":"Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R\/R MF) and other advanced myeloid neoplasms: A phase 1 study","volume":"7","author":"Watts","year":"2023","journal-title":"HemaSphere"},{"key":"key20240523092012_b165-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s41416-020-01077-z","article-title":"First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours","volume":"123","author":"Ameratunga","year":"2020","journal-title":"Br J Cancer"},{"key":"key20240523092012_b166-or-51-6-08733","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V124.21.117.117","article-title":"A Phase 1 Study of the BET-Bromodomain inhibitor OTX015 in patients with advanced acute leukemia","volume":"124","author":"Dombret","year":"2014","journal-title":"Blood"},{"key":"key20240523092012_b167-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: A novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"key":"key20240523092012_b168-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib Trial With Birabresib, a Small-Molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20240523092012_b169-or-51-6-08733","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.annonc.2020.01.025","article-title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin's lymphoma","volume":"31","author":"Moreno","year":"2020","journal-title":"Ann Oncol"},{"key":"key20240523092012_b170-or-51-6-08733","first-page":"504","article-title":"Bromodomain inhibitors: What does the future hold?","volume":"16","author":"Bhattacharya","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20240523092012_b171-or-51-6-08733","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1182\/blood-2019-127119","article-title":"MANIFEST, a Phase 2 Study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi), as monotherapy or \u2018Add-on\u2019 to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"key20240523092012_b172-or-51-6-08733","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-1429","article-title":"Phase I results of bromodomain and Extra-terminal inhibitor PLX51107 in combination with azacitidine in patients with Relapsed\/Refractory myeloid malignancies","volume":"29","author":"Senapati","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20240523092012_b173-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1200\/JCO.2018.36.15_suppl.2550","article-title":"Phase ib\/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors","volume":"36","author":"Patnaik","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20240523092012_b174-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1080\/10428194.2021.1881509","article-title":"A dose escalation study of RO6870810\/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"62","author":"Roboz","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"key20240523092012_b175-or-51-6-08733","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"key20240523092012_b176-or-51-6-08733","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2019.37.15_suppl.3085","article-title":"First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed\/refractory (RR) malignant solid tumor and lymphoma: Preliminary data","volume":"37","author":"Wang","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20240523092012_b177-or-51-6-08733","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.3390\/cancers14174079","article-title":"BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: Results from a Phase 1\/2a trial","volume":"14","author":"Hilton","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20240523092012_b178-or-51-6-08733","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1111\/bcp.15137","article-title":"A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor","volume":"88","author":"Brown","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"key20240523092012_b179-or-51-6-08733","doi-asserted-by":"publisher","first-page":"555591","DOI":"10.3389\/fncel.2020.555591","article-title":"Inhibition of Brd4 by JQ1 promotes functional recovery from spinal cord injury by activating autophagy","volume":"14","author":"Li","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"key20240523092012_b180-or-51-6-08733","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.taap.2016.03.013","article-title":"Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice","volume":"300","author":"Lee","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"key20240523092012_b181-or-51-6-08733","doi-asserted-by":"publisher","first-page":"33853","DOI":"10.18632\/oncotarget.26127","article-title":"Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells","volume":"9","author":"Bakshi","year":"2018","journal-title":"Oncotarget"},{"key":"key20240523092012_b182-or-51-6-08733","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","article-title":"Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer","volume":"394","author":"Leal","year":"2017","journal-title":"Cancer Lett"},{"key":"key20240523092012_b183-or-51-6-08733","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/ijms20071527","article-title":"The BET bromodomain inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats","volume":"20","author":"Piquereau","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20240523092012_b184-or-51-6-08733","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ijc.33989","article-title":"Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"}],"container-title":["Oncology Reports"],"original-title":[],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:20:37Z","timestamp":1716445237000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/or.2024.8733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":184,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,12]]}},"URL":"https:\/\/doi.org\/10.3892\/or.2024.8733","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"article-number":"74"}}